3349
Cosmos Pharmaceutical Corporation
2026/01/13
For the second quarter of the fiscal year ending May 2026, consolidated net sales were 537,175 million yen (6.2% increase YoY), operating income was 20,676 million yen (1.6% increase YoY), and net income attributable to owners of parent for the interim period was 14,648 million yen (1.5% increase YoY).